Search of RelB-NFkB2 signal inhibitor using Glioma-initiating cells
Project/Area Number |
16K18447
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | Hokkaido University |
Principal Investigator |
Ohtsu Naoki 北海道大学, 遺伝子病制御研究所, 助教 (10588403)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | Glioblastoma: multiform / Glioma-initiating cell / NF-kB pathway / Eva1 / Genome editing / RelA / RelB / グリオブラストーマ / グリオーマ幹細胞 / NFkB2 / Glioblastoma / NF-kB2 / Chemical Screening / NF-kB / 分子標的薬 / Chemical screening / NF-kN |
Outline of Final Research Achievements |
Glioblastoma multiform is malignant Brain tumor. There is no anti-cancer drug for gliomas other than temozolomide, and if there is no effect of temozolomide, there is no other choice. Our glioma studies revealed that the RelB-NF-κB2 signal pathway is activated in GBM. Therefore, suppressing RelB-NF-κB2 signal is effective for the treatment of glioma. Therefore, in order to search for RelB-NF-κB2 signal inhibitors, we developed RelB signal monitoring cells that did not recognize RelA signal.
|
Academic Significance and Societal Importance of the Research Achievements |
RelB遺伝子の活性化モニタリング細胞を開発することにより、RelB活性化型のGBMに対する抗がん剤の検索が可能になった。このことによりGBMに対する治療の選択肢を増やし、発症後の生存年数や病状が抑えられた期間を延長させること及び再発の防止ができる可能性を見出した。またGBMにおいてもCrispr/Cas9システムを用いたゲノム編集が可能であったため、Eva1やRelBを分子標的としてゲノム編集を用いたこれまでにない治療方法開発の方向性を見出した。
|
Report
(4 results)
Research Products
(8 results)
-
[Journal Article] Chemical screening identifies EUrd as a novel inhibitor against Temozolomide-resistant glioblastoma-initiating cells.2016
Author(s)
Tsukamoto Y, Ohtsu N, Echizenya S, Otsuguro S, Ogura R, Natsumeda M, Isogawa M, Aoki H, Ichikawa S, Sakaitani M, Matsuda A, Maenaka K, Fujii Y, Kondo T.
-
Journal Title
Stem Cells
Volume: -
Issue: 8
Pages: 2016-2025
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-